Needham Maintains Buy on NeoGenomics, Raises Price Target to $22
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsPrice Target
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $19 to $22.
Needham analyst Mike Matson maintains NeoGenomics (NASDAQ:NEO) with a Buy and raises the price target from $19 to $22.